Nordea Investment Management AB Buys 260,089 Shares of Abbott Laboratories $ABT

Nordea Investment Management AB raised its stake in Abbott Laboratories (NYSE:ABT) by 79.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 589,519 shares of the healthcare product maker’s stock after acquiring an additional 260,089 shares during the period. Nordea Investment Management AB’s holdings in Abbott Laboratories were worth $73,967,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Cloud Capital Management LLC bought a new stake in shares of Abbott Laboratories in the third quarter valued at about $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories during the third quarter worth about $31,000. Delos Wealth Advisors LLC bought a new position in Abbott Laboratories during the second quarter valued at about $32,000. Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories in the 3rd quarter worth approximately $33,000. Finally, Copia Wealth Management bought a new stake in shares of Abbott Laboratories in the 3rd quarter worth approximately $38,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT opened at $104.87 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The business’s fifty day moving average price is $112.36 and its two-hundred day moving average price is $122.77. Abbott Laboratories has a fifty-two week low of $104.10 and a fifty-two week high of $139.06. The stock has a market capitalization of $182.65 billion, a price-to-earnings ratio of 28.19, a price-to-earnings-growth ratio of 1.68 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the previous year, the company earned $1.34 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s payout ratio is 67.74%.

Insider Activity

In other news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Elizabeth C. Cushman sold 263 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the transaction, the executive vice president directly owned 38,573 shares in the company, valued at $4,458,267.34. The trade was a 0.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on ABT shares. Leerink Partners cut their target price on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Citigroup decreased their price target on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Evercore reduced their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Oppenheimer decreased their target price on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.